Photo of Kathryn A. Chung, M.D.

Kathryn A. Chung M.D.

Dr. Chung earned her medical degree from the University of Alberta. She is board certified in internal medicine (1998) and neurology (2003). She received her training in movement disorders from OHSU.

She joined the OHSU movement disorders faculty in 2004. She is currently an associate professor of neurology with the OHSU Parkinson Center and the Parkinson's Disease Research, Education, and Clinical Center (PADRECC) at the Portland VAMC.

Her research interests are focused primarily on Parkinson's disease. Her special interests are the understanding and treatment of dyskinesia, gait and balance abnormailities, neuroprotective strategies, and the study of biomarkers in Parkinson's disease.

Dr. Chung is an expert clinician for all movement disorders and Tourettes syndrome.

Read more
  • Residency:

    • Internal medicine, University of Toronto, Canada
  • Fellowship:

    • Movement disorders, Portland Veterans Affairs Medical Center, 2004
  • Certifications:

    • Internal medicine, 1998


  • "Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease" Neurology October 5 2010
  • "Which dyskinesia scale best detects treatment response?" Movement Disorders March 2013
  • "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression" Annals of Neurology March 2011
  • "CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases" American Journal of Clinical Pathology April 2008
  • "CSF Aβ42 and tau in Parkinson's disease with cognitive impairment" Movement Disorders November 2010
  • "Short-term paroxetine treatment does not alter the motor response to levodopa in PD" Neurology May 24 2005
  • "Evaluation of mild cognitive impairment subtypes in Parkinson's disease" Movement Disorders  2014
  • "SNCA variant associated with Parkinson disease and plasma α-synuclein level" Archives of Neurology November 2010
  • "Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease" Parkinsonism and Related Disorders July 1 2015
  • "Recognizing and treating neuropsychiatric symptoms in parkinson's disease" Journal of Clinical Outcomes Management July 1 2015
  • "Dyskinesia and the antiparkinsonian response always temporally coincide" Neurology April 2010
  • "Phosphorylated α-synuclein in Parkinson's disease" Science Translational Medicine February 15 2012
  • "People with parkinson's disease and normal MMSE score have a broad range of cognitive performance" Movement Disorders  2014
  • "DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease" Brain March 2010
  • "Objective measurement of dyskinesia in Parkinson's disease using a force plate" Movement Disorders April 15 2010
  • "Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy" American Journal of Pathology April 2011
  • "Bilateral deep brain stimulation targeting ventralis intermedius nucleus to treat a professional musician's task-specific tremor" Movement Disorders November 2013
  • "Glycoproteomics in neurodegenerative diseases" Mass Spectrometry Reviews January 2010
  • "Common variation in the LRRK2 gene is a risk factor for Parkinson's disease" Movement Disorders December 2012
  • "APOE ε4 increases risk for dementia in pure synucleinopathies" JAMA Neurology  2013
  • "Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease" Neuroscience Letters August 2010
  • "Pacific northwest udall center of excellence clinical consortium" Journal of Parkinson's Disease  2013
  • "Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome study" Movement Disorders March 2012
  • "Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform" Journal of Proteome Research February 2008
  • "Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and alzheimer's disease" Annals of Neurology June 2011
  • "APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease" JAMA Neurology November 1 2014
  • "Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders" Journal of Alzheimer's Disease  2006
  • "Cognitive profile of LRRK2-related Parkinson's disease" Movement Disorders April 15 2015
  • "Effect of augmenting cholinergic function on gait and balance" BMC Neurology December 23 2015
  • "GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease" Movement Disorders January 1 2016

Additional information

Edit profile